Exploring Psoriasis in Depth: Progress in Treatment Strategies and Disease Mechanisms

Sharveen, K

Page 9

Journal of MedVerse Research & Practice

Exploring Psoriasis in Depth: Progress in Treatment Strategies and

Disease Mechanisms

Dr. S Sharveen

Department of Pharmaceutics

School of Pharmaceutical Education and Research, Karaikal

Email: sharveens64@gmail.com

Submission Date: 25.12.2024

Accepted Date: 21.01.2025

Published Date: 31.01.2025

article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits

unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Abstract

Psoriasis is a chronic, immune-mediated inflammatory disease characterized by erythematous, scaly plaques and

may be associated with systemic comorbidities, including psoriatic arthritis, cardiovascular disease, metabolic

disorders, and psychological distress. Its pathogenesis involves genetic susceptibility, immune dysregulation, and

environmental triggers, with the interleukin (IL)-23/IL-17 pathway playing a central role in inflammatory

processes. This review discusses the mechanisms underlying psoriasis, its clinical manifestations, diagnostic

approaches, and current and emerging treatment strategies. Conventional management includes topical therapies,

phototherapy, and systemic agents such as methotrexate and cyclosporine. Targeted biologic therapies that inhibit

tumour necrosis factor-alpha, IL-17, and IL-23 have expanded treatment options, while small-molecule therapies

provide additional alternatives for selected patients. Clinical assessment remains the primary diagnostic approach,

with skin biopsy and other investigations used when clinically indicated. Despite therapeutic advances, challenges

persist regarding treatment response, long-term safety, affordability, access to care, and the management of

associated comorbidities. An individualized, multidisciplinary approach that considers disease severity, patient

characteristics, comorbid conditions, and treatment preferences is important for optimizing care. Further research is

needed to clarify long-term treatment outcomes, improve access to effective therapies, and strengthen evidence for

personalized psoriasis management.

Keywords: Psoriasis; Immune-mediated inflammation; Pathogenesis; Biologic therapy; Treatment strategies;

Comorbidities; Personalized medicine.

I

ntroduction

Psoriasis is a chronic, immune-mediated inflammatory disease primarily affecting the skin and

characterized by well-demarcated erythematous plaques with scaling. Its clinical presentation and severity

vary among individuals, and the disease may substantially affect physical functioning, psychological

well-being, and quality of life. Psoriasis is also associated with comorbidities such as psoriatic arthritis,

cardiovascular disease, metabolic disorders, and mental health conditions. Its development and

progression involve interactions between genetic susceptibility, immune dysregulation, and

environmental factors. Understanding these mechanisms is important for improving disease recognition,

guiding treatment selection, and addressing the broader health needs of affected individuals.[1]

Psoriasis pathogenesis involves interactions between innate and adaptive immune responses, genetic

susceptibility, and environmental influences. Dendritic cells and T lymphocytes contribute to

inflammatory signalling through cytokines, particularly the IL-23/IL-17 pathway and tumour necrosis

factor-alpha (TNF-α). These inflammatory mediators promote keratinocyte activation and proliferation,

REVIEW ARTICLE

Page 10

contributing to the characteristic epidermal changes observed in psoriatic lesions. Genetic susceptibility

loci, including HLA-C, are associated with disease development, while additional immune-related

pathways contribute to differences in clinical presentation and disease severity. Environmental factors,

including infections, psychological stress, skin injury, and certain lifestyle exposures, may trigger or

exacerbate disease in susceptible individuals. Further research into these mechanisms continues to inform

the development of targeted therapies. [2].

Clinical Variants and Epidemiology

Plaque psoriasis is the most common form, but other subtypes include guttate, inverse, pustular, and

erythrodermic psoriasis. The disease varies globally, with higher prevalence in Europe and North

America (~2–3%) and lower rates in Asian countries (<0.5%). Psoriasis typically emerges between ages

15–35, with a secondary peak between 55–60 years [3].

The disease varies globally, with higher prevalence in Europe and North America (~2–3%) and lower

rates in Asian countries (The epidemiology of psoriasis varies across geographical regions and

populations, reflecting differences in genetic background, environmental exposures, diagnostic practices,

and study methods. The disease can develop at any age, although onset commonly occurs during

adolescence or adulthood. Its clinical forms include plaque, guttate, inverse, pustular, and erythrodermic

psoriasis. Plaque psoriasis is the most common form, while pustular and erythrodermic presentations may

be associated with severe disease and require prompt clinical assessment. Reliable comparisons of

regional prevalence and age at onset require population-based studies using clearly defined diagnostic

criteria.

Advances in Treatment

Traditional therapies include topical agents, phototherapy, and systemic drugs like methotrexate and

cyclosporine. The advent of biologics targeting IL-17, IL-23, and TNF-α has revolutionized disease

management, offering improved control. However, challenges such as high costs, accessibility issues, and

treatment resistance remain. Newer therapies, including JAK and PDE4 inhibitors, provide alternatives

for non-responders. Emerging research into the gut-skin microbiome and personalized medicine

approaches may further refine treatment strategies. Despite significant advancements in psoriasis

management, long-term disease control requires a comprehensive approach addressing immune

mechanisms, genetic factors, and environmental influences. Ongoing research into novel therapeutic

targets, early diagnosis, and individualized treatment strategies will be essential in improving patient

outcomes [4].

Role of Environmental Triggers and Microbiome

Psoriasis is a multifactorial disease in which environmental stimuli modulate genetic susceptibility,

thereby contributing to the onset and exacerbation of the condition. Psoriasis is known to be influenced by

a variety of environmental factors, such as stress, infections, and lifestyle choices.

Triggers of Environmental

Stress is a recognized trigger for psoriasis exacerbations, perhaps because to its impact on immunological

dysregulation. The hypothalamic-pituitary-adrenal (HPA) axis is stimulated by psychological stress,

leading to the secretion of cortisol. This hormone may affect immunological responses and stimulate

inflammation. Guttate psoriasis is linked to infections, especially streptococcal pharyngeal infections.

Psoriasis lesions may be triggered or aggravated by several circumstances, including tobacco use,

excessive alcohol intake, skin damage (Köbner phenomenon), and certain pharmaceuticals [5].

Page 11

Influence of the Microbiome

The human microbiome's intestinal and skin microbiota play a crucial role in controlling inflammation

and immunological responses in psoriasis. Studies have investigated alterations in the skin and gut

microbiomes of individuals with psoriasis. Differences in microbial composition have been reported, but

findings vary across populations and research methods, and the causal relationship between microbiome

changes and psoriasis remains incompletely understood. Interactions between microbial communities and

host immune responses may contribute to inflammatory processes in some patients. Although

microbiome-directed interventions, including probiotics and dietary approaches, are being investigated,

their clinical effectiveness for psoriasis management requires further evaluation. Such interventions

should not be presented as established substitutes for evidence-based psoriasis treatment.

Microbial imbalances may intensify cutaneous inflammation by stimulating immunological responses via

pattern recognition receptors (PRRs) Systemic inflammation has also been connected to gut microbiome

dysbiosis, which further affects psoriasis severity. The therapeutic advantages of re- establishing a

healthy microbiome by topical therapies, probiotics, or dietary modifications may aid in the management

of psoriasis. Formulating tailored strategies for the prevention and management of psoriasis requires

comprehension of the interaction between environmental variables and the microbiome [6].

Diagnostic Approaches in Psoriasis

Figure 1. Overview of diagnostic approaches to psoriasis, including clinical evaluation,

histopathology, dermoscopy, selected imaging techniques, and investigational biomarkers.

Clinical evaluation, including patient history and physical exam, is the primary method for diagnosing

psoriasis. The diagnosis relies on characteristic features, such as reddened lesions with silvery scales,

typically on the scalp, elbows, and knees. In rare or ambiguous cases, histological analysis can be

beneficial. Psoriasis is often confirmed through skin biopsy findings of hyperkeratosis, acanthosis, and

elongated rete ridges. Recent advancements have focused on dermoscopy, a non-invasive approach [7].

Clinical Presentation and Subtypes

Psoriasis is characterized by erythematous plaques covered with silvery-white scales, commonly affecting

the scalp, elbows, and knees. Patients may experience itching, burning, or pain. Nail involvement, such as

subungual hyperkeratosis, onycholysis, and discoloration, is also frequent. Additionally, psoriatic arthritis

may develop, leading to joint complications.

Page 12

Psoriasis presents in several subtypes:

• Plaque Psoriasis: The most prevalent form, featuring well-defined, raised, scaly plaques, usually on

the scalp, elbows, and knees.

• Guttate Psoriasis: Small, drop-like lesions often triggered by infections, particularly streptococcal

throat infections.

• Pustular Psoriasis: Characterized by white pustules surrounded by inflamed skin, which may be

localized or widespread.

• Inverse Psoriasis: Smooth, erythematous lesions found in skin folds, such as the axillae and groin,

lacking the typical scaling.

• Erythrodermic Psoriasis: A rare but severe form causing widespread redness, scaling, and systemic

complications.

Biomarkers and Diagnostic Advances

Recent research has identified key biomarkers such as IL-17, IL-23, TNF-α, and CRP, which aid in

disease assessment and therapeutic monitoring. Advanced imaging techniques, including confocal laser

scanning microscopy and optical coherence tomography (OCT), enable detailed visualization of psoriatic

lesions. Serum biomarkers, such as S100 proteins, provide insights into disease activity, while genetic

markers like HLA-C improve classification and facilitate personalized treatment approaches [8].

Imaging Techniques in Psoriasis

Several imaging techniques have been investigated to characterize psoriatic skin changes and assess

disease activity. Dermoscopy can help visualize vascular patterns and scaling, while optical coherence

tomography and confocal microscopy provide detailed images of superficial skin structures in selected

settings. High-resolution ultrasound may be used to assess skin thickness and vascular changes, although

its application depends on the clinical context. Magnetic resonance imaging is particularly useful when

evaluating suspected musculoskeletal involvement, including inflammatory changes associated with

psoriatic arthritis. These techniques may complement clinical assessment, but their availability,

validation, and role in routine psoriasis management vary.

Current Therapeutic Approaches

Psoriasis treatment aims to reduce inflammation, control skin lesions, improve quality of life, and prevent

or manage associated complications. Treatment selection depends on disease severity, anatomical

distribution, comorbidities, previous treatment response, contraindications, and patient preferences.

Available options include topical therapies, phototherapy, conventional systemic agents, targeted oral

treatments, and biologic therapies.

Modern imaging tools enhance diagnostic precision and treatment monitoring:

Topical treatments: Topical corticosteroids and vitamin D analogues are commonly used for localized

psoriasis. Other options may include topical calcineurin inhibitors for selected sensitive areas and other

topical agents, depending on the clinical presentation.

Phototherapy: Narrowband ultraviolet B phototherapy is an established treatment option for selected

patients with more extensive disease. Psoralen plus ultraviolet A therapy may be considered in

appropriate circumstances, taking into account its potential long-term adverse effects.

Conventional systemic therapies: Methotrexate, cyclosporine, and acitretin may be used in selected

patients with moderate-to-severe psoriasis. Treatment choice requires consideration of contraindications,

comorbidities, reproductive considerations where relevant, and appropriate safety monitoring.

Page 13

Biologic therapies: Biologic agents targeting TNF-α, IL-17, or IL-23 pathways are important options for

selected patients with moderate-to-severe disease. Their effectiveness, safety, contraindications, and

monitoring requirements differ by agent.

Targeted oral therapies: Oral agents such as apremilast and selected other targeted treatments may be

appropriate for particular patients. Their indications, efficacy, and safety profiles differ, and treatment

selection should follow current clinical guidance. Treatment should be individualized and reviewed

periodically to assess effectiveness, tolerability, adherence, and the need for adjustment.

Figure 2. Overview of treatment options for psoriasis, including topical therapies,

phototherapy, conventional systemic agents, and biologic therapies.

Conventional and Emerging Psoriasis Treatments

Traditional Therapies

Psoriasis treatment primarily involves topical therapies and phototherapy. Corticosteroids remain the

most widely used, reducing inflammation and scaling. Vitamin D analogs, such as calcipotriene, regulate

epidermal cell growth, while coal tar and retinoids like tazarotene aid in normalizing skin turnover. For

moderate to severe cases, phototherapy, particularly narrowband UVB, is the preferred option due to its

efficacy and lower risk profile. PUVA therapy, though effective, has limitations due to potential long-

term skin damage [10].

Systemic and Biologic Therapies

Systemic treatments, including methotrexate, cyclosporine, and acitretin, help manage severe psoriasis by

modulating immune responses or slowing excessive cell proliferation. However, these drugs require

monitoring due to potential adverse effects, such as liver and kidney toxicity. Biologic agents have

transformed treatment, offering targeted inhibition of inflammatory pathways. TNF-α blockers

(adalimumab, etanercept) and newer IL-17 and IL-23 inhibitors (secukinumab, guselkumab) provide

sustained remission with fewer side effects [11].

Small-Molecule Therapies

Small-molecule therapies provide oral treatment options for selected inflammatory diseases. Apremilast, a

phosphodiesterase 4 (PDE4) inhibitor, is an established option for selected patients with psoriasis and

psoriatic arthritis. Other targeted oral agents may be available for specific indications, depending on the

drug and jurisdiction. Janus kinase (JAK) inhibitors should not be described as a general class of

Page 14

established psoriasis treatments without specifying the individual drug, its approved indication, and the

supporting evidence. Selection of targeted oral therapy requires consideration of efficacy,

contraindications, adverse effects, and applicable prescribing guidance.

Future Directions and Challenges

Future psoriasis research includes the investigation of additional therapeutic targets, biomarkers,

treatment-response predictors, and strategies for individualizing care. Advances in molecular biology and

gene-editing technologies may contribute to a better understanding of disease mechanisms, but their role

in clinical psoriasis treatment remains investigational. Major challenges include differences in treatment

response, long-term disease control, treatment costs, access to specialist care, and the management of

associated comorbidities. Future studies should prioritize clinically meaningful outcomes, long-term

safety, comparative effectiveness, and equitable access to evidence-based treatments.

Addressing Comorbidities

Psoriasis is associated with several comorbid conditions, including psoriatic arthritis, cardiovascular

disease, metabolic disorders, and psychological distress. The presence of these conditions may influence

treatment selection, disease burden, and quality of life. Clinical care should therefore include appropriate

assessment of joint symptoms, cardiometabolic risk factors, and mental health concerns. A

multidisciplinary approach involving dermatology and other relevant specialties may help address the

broader health needs of patients. Screening and management should be guided by clinical presentation

and current recommendations.

Long-Term Safety, Treatment Resistance, and Future Outlook

Safety Concerns and Access to Care

The safety of psoriasis therapies should be evaluated according to the individual drug, its mechanism of

action, the patient's clinical profile, and the duration of treatment. Biologic and systemic therapies may

require screening, monitoring, and precautions that vary by treatment class. Decisions should balance

expected clinical benefits against potential adverse effects and relevant comorbidities. Affordability,

geographical availability, and access to specialist services can also affect treatment continuity. Improving

access to appropriate therapy, patient education, and follow-up care remains important for effective long-

term disease management.

Challenges in Treatment Response

Some patients do not achieve an adequate response to treatment, while others experience a decline in

effectiveness over time. Treatment outcomes may be influenced by disease severity, comorbidities,

adherence, treatment duration, and individual differences in response. Immunogenicity may contribute to

reduced effectiveness with certain biologic agents, but it is not the sole explanation for treatment failure.

Assessment should include confirmation of the diagnosis, evaluation of adherence and tolerability, review

of comorbidities, and consideration of alternative treatment options when appropriate. Individualized

treatment decisions should be based on clinical assessment and available evidence.

Summary

Psoriasis is a chronic, immune-mediated inflammatory disease arising from interactions between genetic

susceptibility, immune dysregulation, and environmental factors. Its clinical manifestations range from

localized plaques to more extensive or severe forms, and some patients develop nail involvement or

psoriatic arthritis. Diagnosis is primarily clinical, with biopsy and selected diagnostic investigations used

when indicated. Treatment options include topical agents, phototherapy, conventional systemic therapies,

Page 15

targeted oral treatments, and biologic agents. The choice of treatment depends on disease severity,

comorbidities, safety considerations, treatment response, and patient preferences. Important challenges

include variable treatment response, long-term disease management, affordability, and access to

appropriate care. Continued research into disease mechanisms, treatment effectiveness, safety, and

individualized care may help improve outcomes for people living with psoriasis.

Conclusion

Psoriasis is a chronic immune-mediated inflammatory disease with diverse clinical manifestations and

potential systemic comorbidities. Improved understanding of the IL-23/IL-17 pathway and other

inflammatory mechanisms has contributed to the development of targeted treatments and expanded

therapeutic options. Nevertheless, effective management requires more than controlling skin lesions; it

also involves recognizing associated conditions, monitoring treatment response and safety, and addressing

barriers to access and adherence. Treatment should be individualized according to disease severity,

comorbidities, contraindications, and patient preferences. Future research should strengthen evidence on

long-term effectiveness, safety, treatment-response predictors, and equitable access to care. Integrating

advances in disease biology with comprehensive clinical management may help improve long-term

outcomes and quality of life for patients with psoriasis.

Declaration

Conflict of Interest: The authors declare that they have no competing interests or conflicts of interest

related to this work.

Funding: Nil

References

1. Ahamad, N., Kar, A., Mehta, S., Dewani, M., Ravichandran, V., Bhardwaj, P., Sharma, S., Banerjee, R.,

2021. Immunomodulatory nanosystems for treating inflammatory diseases. Biomaterials.

https://doi.org/10.1016/j.biomaterials.2021.120875

2. Armstrong, A.W., Bohannan, B., Mburu, S., Coates, L.C., Ogdie, A., Alarcon, I., Kasparek, T., Frade, S.,

Barrio, S.F., Augustin, M., 2023. Patient Perspectives on Psoriatic Disease Burden: Results from the

Global Psoriasis and Beyond Survey. Dermatology. https://doi.org/10.1159/000528945

3. Attri, D.S., Rathour, A., Ray, R.K., Kumar, V., 2023. Formulation and evaluation of hydrogel for topical

drug delivery of Zingiber officinale Rosc . and Withania somnifera ( L .) Dunal to increase the

bioavailability of oils for the treatment of arthritis 12, 1–10.

4. Bakewell, C., Aydin, S.Z., Ranganath, V.K., Eder, L., Kaeley, G.S., 2020. Imaging Techniques:Options for

the Diagnosis and Monitoring of Treatment of Enthesitis in Psoriatic Arthritis. Journal of Rheumatology.

https://doi.org/10.3899/jrheum.190512

5. Bakshi, H., Nagpal, M., Singh, M., Dhingra, G.A., Aggarwal, G., 2020. Treatment of Psoriasis: A

Comprehensive Review of Entire Therapies. Current Drug Safety.

https://doi.org/10.2174/1574886315666200128095958

6. Balan, R., Grigoras, A., Popovici, D., Amalinei, C., 2019. The histopathological landscape of the major

psoriasiform dermatoses. Archive of Clinical Cases. https://doi.org/10.22551/2019.24.0603.10155

7. Bhagwat, A.P., Madke, B., 2023. The Current Advancement in Psoriasis. Cureus.

https://doi.org/10.7759/cureus.47006 Burger, B., Sagiorato, R.N., Cavenaghi, I., Rodrigues, H.G., 2023.

Abnormalities of Sphingolipids Metabolic Pathways in the Pathogenesis of Psoriasis. Metabolites.

https://doi.org/10.3390/metabo13020291

8. Pourani MR, Abdollahimajd F, Zargari O, Shahidi Dadras M. Soluble biomarkers for diagnosis,

monitoring, and therapeutic response assessment in psoriasis. J Dermatolog Treat.

2022;33(4):1967-1974. doi:10.1080/09546634.2021.1966357.

Page 16

9. Campbell, K., Li, K., Yang, F., Branigan, P., Elloso, M.M., Benson, J., Orlovsky, Y., Chen, Y., Garcet, S.,

Krueger, J.G., 2023. Guselkumab More Effectively Neutralizes PsoriasisAssociated Histologic,

Transcriptomic, and Clinical Measures than Ustekinumab. ImmunoHorizons.

https://doi.org/10.4049/immunohorizons.2300003

10. Canal-García, E., Bosch-Amate, X., Belinchón, I., Puig, L., 2022. Nail Psoriasis. Actas

DermoSifiliograficas. https://doi.org/10.1016/j.ad.2022.01.006

11. Celoria, V., Rosset, F., Pala, V., Dapavo, P., Ribero, S., Quaglino, P., Mastorino, L., 2023. The Skin

Microbiome and Its Role in Psoriasis: A Review. Psoriasis: Targets and Therapy.

https://doi.org/10.2147/ptt.s328439

12. Chen, C., Che, K., Guo, Y., Huang, Q., Hu, X., Yu, B., 2023. Effect of the age of onset on epidemiology,

clinical features, and comorbidity of geriatric psoriasis. The Journal of Dermatology 50, 1156–1161.

https://doi.org/10.1111/1346-8138.16856

13. Chen, T., Zhu, S.J., Xu, S., Wang, Y.Q., Aji, A., Zhang, C., Wang, H., Li, F.L., Chu, Y.X., 2023. Resting-

state fMRI reveals changes within the anxiety and social avoidance circuitry of the brain in mice with

psoriasis-like skin lesions. Experimental Dermatology. https://doi.org/10.1111/exd.14914

14. Damiani, G., Conic, R.R.Z., Pigatto, P.D.M., Carrera, C.G., Franchi, C., Cattaneo, A., Malagoli,P., Uppala,

R., Linder, D., Bragazzi, N.L., Grossi, E., 2020. Predicting Secukinumab Fast Responder Profile in

Psoriatic Patients: Advanced Application of Artificial-Neural Networks (ANNs). Journal of Drugs in

Dermatology. https://doi.org/10.36849/JDD.2020.5006